Literature DB >> 28071677

Renal-cell carcinoma in 2016: Advances in treatment - jostling for pole position.

Laurence Albiges1, Toni K Choueiri2.   

Abstract

Entities:  

Mesh：

Year:  2017        PMID： 28071677     DOI： 10.1038/nrclinonc.2016.224

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  11 in total

1.  Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma.

Authors:  Toni K Choueiri; Bernard Escudier; Thomas Powles; Paul N Mainwaring; Brian I Rini; Frede Donskov; Hans Hammers; Thomas E Hutson; Jae-Lyun Lee; Katriina Peltola; Bruce J Roth; Georg A Bjarnason; Lajos Géczi; Bhumsuk Keam; Pablo Maroto; Daniel Y C Heng; Manuela Schmidinger; Philip W Kantoff; Anne Borgman-Hagey; Colin Hessel; Christian Scheffold; Gisela M Schwab; Nizar M Tannir; Robert J Motzer
Journal:  N Engl J Med       Date:  2015-09-25       Impact factor: 91.245

2.  Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial.

Authors:  Toni K Choueiri; Bernard Escudier; Thomas Powles; Nizar M Tannir; Paul N Mainwaring; Brian I Rini; Hans J Hammers; Frede Donskov; Bruce J Roth; Katriina Peltola; Jae Lyun Lee; Daniel Y C Heng; Manuela Schmidinger; Neeraj Agarwal; Cora N Sternberg; David F McDermott; Dana T Aftab; Colin Hessel; Christian Scheffold; Gisela Schwab; Thomas E Hutson; Sumanta Pal; Robert J Motzer
Journal:  Lancet Oncol       Date:  2016-06-05       Impact factor: 41.316

3.  Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial.

Authors:  Robert J Motzer; Thomas E Hutson; Hilary Glen; M Dror Michaelson; Ana Molina; Timothy Eisen; Jacek Jassem; Jakub Zolnierek; Jose Pablo Maroto; Begoña Mellado; Bohuslav Melichar; Jiri Tomasek; Alton Kremer; Han-Joo Kim; Karen Wood; Corina Dutcus; James Larkin
Journal:  Lancet Oncol       Date:  2015-10-22       Impact factor: 41.316

4.  Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial.

Authors:  David Cella; Viktor Grünwald; Paul Nathan; Justin Doan; Homa Dastani; Fiona Taylor; Bryan Bennett; Michael DeRosa; Scott Berry; Kristine Broglio; Elmer Berghorn; Robert J Motzer
Journal:  Lancet Oncol       Date:  2016-06-06       Impact factor: 41.316

5.  Updated European Association of Urology Guidelines Regarding Adjuvant Therapy for Renal Cell Carcinoma.

Authors:  Axel Bex; Laurence Albiges; Börje Ljungberg; Karim Bensalah; Saeed Dabestani; Rachel H Giles; Fabian Hofmann; Milan Hora; Markus A Kuczyk; Thomas B Lam; Lorenzo Marconi; Axel S Merseburger; Michael Staehler; Alessandro Volpe; Thomas Powles
Journal:  Eur Urol       Date:  2016-12-13       Impact factor: 20.096

6.  Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma.

Authors:  Robert J Motzer; Carlos H Barrios; Tae Min Kim; Silvia Falcon; Thomas Cosgriff; W Graydon Harker; Vichien Srimuninnimit; Ken Pittman; Roberto Sabbatini; Sun Young Rha; Thomas W Flaig; Ray Page; Sevil Bavbek; J Thaddeus Beck; Poulam Patel; Foon-Yiu Cheung; Sunil Yadav; Edward M Schiff; Xufang Wang; Julie Niolat; Dalila Sellami; Oezlem Anak; Jennifer J Knox
Journal:  J Clin Oncol       Date:  2014-07-21       Impact factor: 44.544

7.  Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non-Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial.

Authors:  Nizar M Tannir; Eric Jonasch; Laurence Albiges; Emre Altinmakas; Chaan S Ng; Surena F Matin; Xuemei Wang; Wei Qiao; Zita Dubauskas Lim; Pheroze Tamboli; Priya Rao; Kanishka Sircar; Jose A Karam; David F McDermott; Christopher G Wood; Toni K Choueiri
Journal:  Eur Urol       Date:  2015-11-26       Impact factor: 20.096

8.  Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy.

Authors:  Alain Ravaud; Robert J Motzer; Hardev S Pandha; Daniel J George; Allan J Pantuck; Anup Patel; Yen-Hwa Chang; Bernard Escudier; Frede Donskov; Ahmed Magheli; Giacomo Carteni; Brigitte Laguerre; Piotr Tomczak; Jan Breza; Paola Gerletti; Mariajose Lechuga; Xun Lin; Jean-Francois Martini; Krishnan Ramaswamy; Michelle Casey; Michael Staehler; Jean-Jacques Patard
Journal:  N Engl J Med       Date:  2016-10-09       Impact factor: 91.245

9.  Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.

Authors:  Robert J Motzer; Bernard Escudier; David F McDermott; Saby George; Hans J Hammers; Sandhya Srinivas; Scott S Tykodi; Jeffrey A Sosman; Giuseppe Procopio; Elizabeth R Plimack; Daniel Castellano; Toni K Choueiri; Howard Gurney; Frede Donskov; Petri Bono; John Wagstaff; Thomas C Gauler; Takeshi Ueda; Yoshihiko Tomita; Fabio A Schutz; Christian Kollmannsberger; James Larkin; Alain Ravaud; Jason S Simon; Li-An Xu; Ian M Waxman; Padmanee Sharma
Journal:  N Engl J Med       Date:  2015-09-25       Impact factor: 91.245

10.  Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial.

Authors:  Naomi B Haas; Judith Manola; Robert G Uzzo; Keith T Flaherty; Christopher G Wood; Christopher Kane; Michael Jewett; Janice P Dutcher; Michael B Atkins; Michael Pins; George Wilding; David Cella; Lynne Wagner; Surena Matin; Timothy M Kuzel; Wade J Sexton; Yu-Ning Wong; Toni K Choueiri; Roberto Pili; Igor Puzanov; Manish Kohli; Walter Stadler; Michael Carducci; Robert Coomes; Robert S DiPaola
Journal:  Lancet       Date:  2016-03-09       Impact factor: 79.321
View more
  4 in total

1.  Cancer, obesity, and diabetes: TKIs exert multiple effects on glucose homeostasis.

Authors:  Minglin Lin; Junfei Jin
Journal:  Nat Rev Clin Oncol       Date:  2017-04-19       Impact factor: 66.675

2.  Prediction of overall survival based upon a new ferroptosis-related gene signature in patients with clear cell renal cell carcinoma.

Authors:  Zhuolun Sun; Tengcheng Li; Chutian Xiao; Shaozhong Zou; Mingxiao Zhang; Qiwei Zhang; Zhenqing Wang; Hailun Zhan; Hua Wang
Journal:  World J Surg Oncol       Date:  2022-04-14       Impact factor: 2.754

3.  The glucose and lipid metabolism reprogramming is grade-dependent in clear cell renal cell carcinoma primary cultures and is targetable to modulate cell viability and proliferation.

Authors:  Cristina Bianchi; Chiara Meregalli; Silvia Bombelli; Vitalba Di Stefano; Francesco Salerno; Barbara Torsello; Sofia De Marco; Giorgio Bovo; Ingrid Cifola; Eleonora Mangano; Cristina Battaglia; Guido Strada; Giuseppe Lucarelli; Robert H Weiss; Roberto A Perego
Journal:  Oncotarget       Date:  2017-12-08

4.  Non-Coding Micro RNAs and Hypoxia-Inducible Factors Are Selenium Targets for Development of a Mechanism-Based Combination Strategy in Clear-Cell Renal Cell Carcinoma-Bench-to-Bedside Therapy.

Authors:  Youcef M Rustum; Sreenivasulu Chintala; Farukh A Durrani; Arup Bhattacharya
Journal:  Int J Mol Sci       Date:  2018-10-29       Impact factor: 5.923
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.